1. Home
  2. KOP vs ALLO Comparison

KOP vs ALLO Comparison

Compare KOP & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koppers Holdings Inc.

KOP

Koppers Holdings Inc.

N/A

Current Price

$50.31

Market Cap

784.7M

ML Signal

N/A

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

N/A

Current Price

$1.66

Market Cap

707.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KOP
ALLO
Founded
1988
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
784.7M
707.6M
IPO Year
2005
2018

Fundamental Metrics

Financial Performance
Metric
KOP
ALLO
Price
$50.31
$1.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
15
Target Price
$52.50
$8.35
AVG Volume (30 Days)
140.4K
8.3M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
0.90%
N/A
EPS Growth
11.38
34.09
EPS
0.35
N/A
Revenue
$1,879,300,000.00
N/A
Revenue This Year
$2.91
N/A
Revenue Next Year
$1.86
$142,416.42
P/E Ratio
$141.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.00
$0.99
52 Week High
$52.25
$4.46

Technical Indicators

Market Signals
Indicator
KOP
ALLO
Relative Strength Index (RSI) 65.29 31.83
Support Level $34.69 $1.56
Resistance Level N/A $1.92
Average True Range (ATR) 1.74 0.11
MACD -0.02 -0.02
Stochastic Oscillator 66.41 8.26

Price Performance

Historical Comparison
KOP
ALLO

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Share on Social Networks: